Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of milvexian after acute coronary syndrome
NL-OMON60622Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Milvexian + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Time to first occurrence of major adverse cardiovascular events. Started Dec 2023; status: completed.
02
Drugs
milvexian
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NL-OMON60622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60622.